Atopic Dermatitis Clinical Trials in Birmingham, Alabama

8 studies are recruiting for atopic dermatitis in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

   The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. …

   Stage

   Not phased

   Ages

   12 and older

   Site

   Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham, Alabama

   Locations

   82 in total

   Run by

   Sanofi

   See if you can join NCT07290803 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

   The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Cahaba Dermatology & Skin Health Center, Birmingham, Alabama

   Locations

   21 in total

   Run by

   Pfizer

   See if you can join NCT07765888 on ClinicalTrials.gov

3. A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

   This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrociti…

   Stage

   Phase 3

   Ages

   2 to 11

   Site

   Cahaba Dermatology & Skin Health Center, Birmingham, Alabama

   Locations

   39 in total

   Run by

   Pfizer

   See if you can join NCT06807281 on ClinicalTrials.gov

4. First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

   This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in human…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Cahaba Dermatology & Skin Health Center, LLC, Birmingham, Alabama

   Locations

   7 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT07527923 on ClinicalTrials.gov

5. Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

   This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Novartis Investigative Site, Birmingham, Alabama

   Locations

   105 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06947993 on ClinicalTrials.gov

6. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   AllerVie Clinical Research, Birmingham, Alabama

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

7. A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

   The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of …

   Stage

   Phase 3

   Ages

   0 to 11

   Site

   Leo Pharma Investigational site, Birmingham, Alabama

   Locations

   72 in total

   Run by

   LEO Pharma

   See if you can join NCT06311682 on ClinicalTrials.gov

8. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

   The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

   Stage

   Not phased

   Ages

   12 and older

   Site

   Galderma Investigational Site - 8893, Birmingham, Alabama

   Locations

   108 in total

   Run by

   Galderma R&D

   See if you can join NCT06988605 on ClinicalTrials.gov